Bone tumor–targeted delivery of theranostic 195mPt-bisphosphonate complexes promotes killing of metastatic tumor cells

Nadar, Robin A.; Franssen, Gerben M.; Dijk, Natasja W M van; Schilden, Karlijn Codee-van der; Weijert, Mirjam de; Oosterwijk, Egbert; Iafisco, Michele; Margiotta, Nicola; Heskamp, Sandra; Beucken, Jeroen J.J.P. van den; Leeuwenburgh, Sander C.G.

doi:10.1016/j.mtbio.2020.100088

Cited by 17 publications

(11 citation statements)

References 44 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the drug-induced AKI animal model is widely used at present, which is highly like human AKI lesions and is closer to the pathophysiological process of AKI. For example, cisplatin is very potent chemotherapeutics with strong nephrotoxicity, which are actively transported to the proximal tubular cells through the organic cation transporter 2 in cisplatin-induced AKI 68 . Cisplatin is hydrolyzed into positively charged electrophile molecules to destroy the mitochondrial respiratory chain complex to increase O 2 .- production in the proximal tubular cells 69 - 72 .…”

Section: Rons Imaging Probesmentioning

confidence: 99%

Emerging early diagnostic methods for acute kidney injury

Xiao¹,

Huang²,

Yang³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Many factors such as trauma and COVID-19 cause acute kidney injury (AKI). Late AKI have a very high incidence and mortality rate. Early diagnosis of AKI provides a critical therapeutic time window for AKI treatment to prevent progression to chronic renal failure. However, the current clinical detection based on creatinine and urine output isn't effective in diagnosing early AKI. In recent years, the early diagnosis of AKI has made great progress with the advancement of information technology, nanotechnology, and biomedicine. These emerging methods are mainly divided into two aspects: First, predicting AKI through models construct by machine learning; Second, early diagnosis of AKI through detection of newly-discovered early biomarkers. Currently, these methods have shown great potential and become an attractive tool for the early diagnosis of AKI. Therefore, it is very important to discuss and summarize these methods for the early diagnosis of AKI. In this review, we first systematically summarize the application of machine learning in AKI prediction algorithms and specific scenarios. In addition, we introduce the key role of early biomarkers in the progress of AKI, and then comprehensively summarize the application of emerging detection technologies for early AKI. Finally, we discuss current challenges and prospects of machine learning and biomarker detection. The review is expected to provide new insights for early diagnosis of AKI, and provided important inspiration for the design of early diagnosis of other major diseases.

show abstract

Section: Rons Imaging Probesmentioning

confidence: 99%

Emerging early diagnostic methods for acute kidney injury

Xiao¹,

Huang²,

Yang³

et al. 2022

Theranostics

View full text Add to dashboard Cite

show abstract

“…In addition, Bi 2 S 3 -Au Schottky-type heterostructures can be adopted as a multifunctional drug delivery platform to combine chemotherapy and RT. This combination therapy has shown great potential in improving the efficiency of RT and minimizing the systemic toxicity of chemotherapeutic drugs (Nadar et al, 2021). Very recently, Nosrati et al (2022) developed a methotrexate and curcumin co-loaded BSA-encapsulated Bi 2 S 3 -Au nanocomposite (Bi 2 S 3 @BSA-Au-BSA-MTX-CUR) for the combined treatment of chemotherapy and RT.…”

Section: Non-o 2 Dependent Radiotherapymentioning

confidence: 99%

Emerging Bismuth Chalcogenides Based Nanodrugs for Cancer Radiotherapy

Huang

Liu

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Radiotherapy (RT), as one of the main methods of clinical tumor treatment, has been applied to the treatment of most solid tumors. However, the effect of RT is compromised by the radiation resistance of tumor hypoxic environment and non-specific damage caused by high-dose radiation. Bismuth chalcogenides (Bi2X3, X = S, Se) based nanodrugs have attracted widespread attention as highly efficient radiosensitizers due to their high photoelectric effect and excellent biocompatibility. More importantly, specially designed nanocomposites can effectively alleviate the radiation resistance of tumor tissues. Here, for the first time, we systematically summarize the latest progresses of Bi2X3 nanodrugs to enhance RT by alleviating the hypoxic tumor microenvironment. These emerging Bi2X3 nanodrugs mainly include three aspects, which are Bi2X3 nanocomposites with high-efficient O2 supply, non-O2-dependent Bi2X3 nanocomposites RT enhancers, and Bi2X3 nanocomposites-based photothermal-enhanced radiosensitizers. These Bi2X3 nanodrugs can effectively overcome the RT resistance of tumor hypoxic microenvironment, and have extremely high therapeutic effects and clinical application prospects. Finally, we put forward the challenges and prospects of Bi2X3 nanomaterials in the field of RT.

show abstract

“…Abundant Auger emissions also make 195m Pt, and 193m Pt (t 1/2 = 4.33 days), potential therapeutic options. [136][137][138] Group 11 (Cu, Ag, Au)…”

Section: Rsc Chemical Biology Reviewmentioning

confidence: 99%